Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule
- 1 January 1991
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 6 (1) , 61-63
- https://doi.org/10.3109/10428199109064880
Abstract
A phase II trial of fludarabine phosphate using a bolus and continuous infusion regimen in previously treated multiple myeloma was performed. No responses were observed in eleven patients. There was no significant non-hematologic toxicity noted. Fludarabine phosphate is inactive in multiple myeloma using this schedule.Keywords
This publication has 4 references indexed in Scilit:
- Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.Journal of Clinical Oncology, 1991
- Phase II study of Fludarabine Phosphate in multiple myelomaInvestigational New Drugs, 1990
- Fludarabine: a new agent with major activity against chronic lymphocytic leukemiaBlood, 1989
- Phase I Clinical Investigation of Fludarabine Phosphate by a Loading-Dose and Continuous-Infusion ScheduleJNCI Journal of the National Cancer Institute, 1988